Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Olink Holding Ab [Publ] ADR (NQ: OLK )

25.85 -0.01 (-0.04%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Olink Holding Ab [Publ] ADR

< Previous 1 2 Next >
Olink reports third quarter 2023 financial results
From Olink Proteomics AB
Via GlobeNewswire
Novogene Asia Pacific Middle East and Africa adopts Olink® Explore HT technology to accelerate multi-omics research with next generation proteomics
From Olink Proteomics AB
Via GlobeNewswire
OLINK HOLDING INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Olink Holding AB - OLK
From Kahn Swick & Foti, LLC
Via Business Wire
OLINK HOLDING INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Olink Holding AB - OLK
From Kahn Swick & Foti, LLC
Via Business Wire
OLK Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Olink Holding AB (publ) Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Thermo Fisher Scientific to Acquire Olink, a Leader in Next-Generation Proteomics
From Thermo Fisher Scientific Inc.
Via Business Wire
Landmark studies utilizing Olink® Explore technology signal a new era for population-scale proteogenomics
From Olink Proteomics AB
Via GlobeNewswire
Announcing the Olink® Target 48 Mouse Cytokine Panel – the next generation in immunoassays designed to accelerate translational research.
Discover more with less. Unmatched specificity and sensitivity deliver translational insights from 1µl of sample. 
From Olink Proteomics AB
Via GlobeNewswire
Eurofins Genomics adopts Olink® technology to advance proteomics research and accelerate precision medicine programs
From Olink Proteomics AB
Via GlobeNewswire
Olink to participate in September investor events
From Olink Proteomics AB
Via GlobeNewswire
Olink reports second quarter 2023 financial results
From Olink Proteomics AB
Via GlobeNewswire
Baylor College of Medicine Human Genome Sequencing Center adopts Olink® Explore HT proteomics platform
From Olink Proteomics AB
Via GlobeNewswire
Olink to report second quarter 2023 financial results on August 9, 2023, and to participate in the Canaccord Genuity 43rd Annual Growth Conference
From Olink Proteomics AB
Via GlobeNewswire
Announcing Olink® Explore HT – A New Era in Proteomics
A High-throughput Protein Biomarker Discovery Platform with Proven Specificity at Any Scale 
From Olink Proteomics AB
Via GlobeNewswire
Revealing the secrets of the human proteome with Olink® Insight: Exploring findings from one of the world's largest health studies
From Olink Proteomics AB
Via GlobeNewswire
Olink to participate in June investor events
From Olink Proteomics AB
Via GlobeNewswire
Olink reports first quarter 2023 financial results
From Olink Proteomics AB
Via GlobeNewswire
Report from the Annual General Meeting of Olink Holding AB (publ) on 17 April 2023
From Olink Proteomics AB
Via GlobeNewswire
Olink to report first quarter 2023 financial results on May 11, 2023
From Olink Proteomics AB
Via GlobeNewswire
Swedish Olink technology enables further development of South African research and innovation
From Olink Proteomics AB
Via GlobeNewswire
Olink publishes 2022 annual report
From Olink Proteomics AB
Via GlobeNewswire
Bruno Rossi joins Olink as Chief Commercial Officer
From Olink Proteomics AB
Via GlobeNewswire
Notice to attend the Annual General Meeting of Olink Holding AB (publ)
From Olink Proteomics AB
Via GlobeNewswire
NUS Medicine implements Olink technology to accelerate precision medicine through next-generation proteomics
From Olink Proteomics AB
Via GlobeNewswire
Olink establishes agreement with Regeneron Genetics Center to scale their proteomics efforts, potentially enabling a new era of drug discovery
From Olink Proteomics AB
Via GlobeNewswire
Olink reports fourth quarter and full year 2022 financial results
From Olink Proteomics AB
Via GlobeNewswire
Olink Holding AB (publ) announces pricing of public offering of American Depositary Shares
From Olink Proteomics AB
Via GlobeNewswire
Olink Holding AB (publ) launches public offering of American Depositary Shares
From Olink Proteomics AB
Via GlobeNewswire
Olink announces preliminary unaudited revenue for the fourth quarter and full year 2022 and provides outlook for 2023
From Olink Proteomics AB
Via GlobeNewswire
Olink to participate in the 41st Annual JP Morgan Healthcare Conference
From Olink Proteomics AB
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.